BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
基本信息
- 批准号:10373039
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AchievementAcuteAdultAffectAlanineAlteplaseAnimal ModelAntihypertensive AgentsAttenuatedAutopsyAwardBehavioralBrainBrain DiseasesBrain InjuriesCardiovascular DiseasesCarrier ProteinsCause of DeathCerebral EdemaCerebrospinal FluidCerebrovascular DisordersCognitiveCollaborationsCommunicationDevelopmentDisclosureDiseaseEdemaExhibitsFree RadicalsFunctional disorderFundingGrantHealthHealthcareHemorrhageHigh PrevalenceHomeostasisHumanHybridsHydrocephalusHypertensionImpairmentInbred SHR RatsInbred WKY RatsInflammationInflammatoryInternationalIon TransportIonsIschemiaIschemic Brain InjuryIschemic StrokeKidneyKnockout MiceLegal patentLysineMaintenanceMalignant - descriptorMediatingMembraneMicrogliaMiddle Cerebral Artery InfarctionMilitary PersonnelMissionModelingMotorMusNADPH OxidaseNatureNervous System PhysiologyNeuraxisNeurogliaNeuroprotective AgentsOligodendrogliaOxidative StressPathogenesisPatientsPersonsPharmacologyPhenotypePhosphorylationPhosphotransferasesPlayPost-Traumatic Stress DisordersPredispositionProductionProlineProtein IsoformsProteinsRattusRecovery of FunctionRegulationReportingResearchResearch Project GrantsRightsRoleScientistSensorimotor functionsSignal TransductionSodium ChlorideStrokeStructure of choroid plexusSuperoxidesSynapsesTechnology TransferTherapeuticTranslational ResearchTraumatic Brain InjuryUnited States Department of Veterans AffairsVeteransbrain tissueburden of illnesscareercell injurychloride-cotransporter potassiumcomorbiditycontrolled cortical impactcytokinecytotoxicdisabilityexcitotoxicityhealth care servicehypertensiveimprovedimproved outcomeinclusion criteriainhibitorinjury and repairinnovationinventionmacrophagenervous system disordernormotensivenovelnovel therapeutic interventionpH Homeostasisprehypertensionpreservationprogramsprotein expressionremyelinationscaffoldsocialstroke interventionstroke modelstroke therapytherapeutic targettissue repairtranslational approachwhite matterwhite matter injury
项目摘要
PROJECT ABSTRACT
Over the past 25 years, I have established an internationally renowned research program on studying membrane
ion transport proteins and their functions in pathophysiology of neurological diseases. We have advanced our
understanding about roles of ion transport proteins (Na+-K+-Cl- cotransporter, Na+/H+ exchanger and Na+/Ca2+
exchangers) in regulation of ionic homeostasis in the central nervous system under disease conditions such as
acute ischemic stroke and traumatic brain injury (TBI). These brain disorders have high prevalence in veterans
and our research is closely related to improving veterans’ health care, and the mission of VA BLRD. In the period
of my RCS, I will conduct two research projects funded by BLR&D merit grants. Since I joined VAPHS as a
Research Health Scientist in 2012, I have built broad collaborations with VA clinicians, VA scientists, and non-
VA scientists. I currently serve as a Co-I on six collaborative projects with VA and non-VA scientists. I will
continue to contribute my expertise to these collaborations.
In the I01BX002891 study, we will investigate efficacy of SPAK inhibitor ZT-1a as a strategy for ischemic stroke
therapy. Evolutionary conserved WNK ["with no lysine" (K)] kinases and the downstream SPAK/OSR1
(Ste20/SPS1-related proline/alanine-rich kinase and oxidative stress-responsive kinase 1) kinases regulate
activities of multiple ion transporters and play important roles in renal salt handling, maintenance of arterial tone,
and hypertension. Na+-K+-2Cl- cotransporter isoform 1 (NKCC1) is one of the major substrates of the WNK-
SPAK/OSR1 kinases. Stimulation of
the
WNK-SPAK kinases increased brain NKCC1 activity via protein
phosphorylation and led to ischemic cell damage through NKCC1-mediated Na+ and Cl- overload, cytotoxic
edema and excitotoxicity. In the initial funding period of BX002891 grant, we discovered that WNK-SPAK/OSR1
kinases are involved in the pathogenesis of ischemic stroke-induced brain damages (JCB&M. 2017). We
concluded that augmented WNK-Cab39-NKCC1 signaling in hypertensive rats is associated with an increased
susceptibility to ischemic brain damage and presents as a novel target for anti-hypertensive and anti-ischemic
stroke therapy. We developed a novel WNK-SPAK inhibitor ZT-1a which shows robust neuroprotective activity
in animal models of ischemic stroke (Nature Communications 2020). Derived from this research, a patent
application (VA Invention Disclosure ID# 2018-313) “
Therapeutic application of ZT-1a and derivatives for brain
disorders”
has been filed via U.S. Department of Veterans Affairs. Assessing ZT-1a and its derivatives as novel
neuroprotective drugs for acute ischemic stroke therapies is innovative and will benefit veterans’ health.
In the second study funded by I01BX004625, we will investigate the roles of microglia-oligodendrocyte
interactions in white matter injury and tissue repair and to explore glia-oriented therapeutic strategies for treating
TBI. Microglia activation plays a role in white matter injury and tissue repair. Regulation of a switch between pro-
inflammatory and adaptive phenotypes of microglia/macrophage is important for oligodendrocyte differentiation,
remyelination, as well as remodeling of synapses. We recently discovered that Na/H exchanger isoform 1 protein
(NHE1)-mediated H+ efflux maintains microglial intracellular pH homeostasis to promote NADPH oxidase
activation, free radical superoxide production, and cytokine secretion. We reported that selective deletion of
microglial Nhe1 in the Cx3cr1-CreER;Nheflox/flox (Nhe1 KO) mice preserved oligodendrocytes and improved
sensorimotor function recovery in an experimental focal ischemic stroke model. Nhe1 KO mice exhibited
increased APC+ mature oligodendrocyte counts and preserved white matter integrity in a controlled cortical
impact-induced TBI model. Especially, post-TBI administration of the NHE1 protein inhibitor HOE642 accelerated
neurological function recovery in mice after either stroke or TBI. We will further investigate NHE1 protein in
modulating microglia-mediated inflammation in remyelination and tissue repair after TBI.
项目摘要
在过去的25年里,我建立了一个国际知名的研究计划,研究膜
离子转运蛋白及其在神经系统疾病病理生理中的作用我们已经提高了我们的
离子转运蛋白(Na+-K+-Cl-共转运蛋白、Na+/H+交换蛋白和Na+/Ca 2+转运蛋白)的作用
交换剂)在疾病条件下调节中枢神经系统中的离子稳态,
急性缺血性中风和创伤性脑损伤(TBI)。这些脑部疾病在退伍军人中的患病率很高
我们的研究与改善退伍军人的医疗保健以及VA BLRD的使命密切相关。期间
在我的RCS中,我将进行两个由BLR&D优异奖赠款资助的研究项目。自从我加入VAPHS以来,
研究健康科学家在2012年,我已经建立了广泛的合作与VA临床医生,VA科学家,和非
科学家们。我目前担任一个Co-I在六个合作项目与VA和非VA科学家。我会
继续为这些合作贡献我的专业知识。
在I 01 BX 002891研究中,我们将研究SPAK抑制剂ZT-1a作为缺血性卒中治疗策略的疗效
疗法进化保守的WNK [“无赖氨酸”(K)]激酶和下游SPAK/OSR 1
(Ste 20/SPS 1相关的脯氨酸/丙氨酸丰富激酶和氧化应激反应激酶1)激酶调节
多种离子转运蛋白的活性,并在肾盐处理、维持动脉张力,
和高血压。Na+-K+-2Cl-协同转运体亚型1(NKCC 1)是WNK-1的主要底物之一。
SPAK/OSR 1激酶。刺激
的
WNK-SPAK激酶通过蛋白质途径增加脑NKCC 1活性
磷酸化,并通过NKCC 1介导的Na+和Cl-过载导致缺血性细胞损伤,细胞毒性
水肿和兴奋性毒性。在BX 002891资助的最初资助期间,我们发现WNK-SPAK/OSR 1
激酶参与缺血性中风诱导的脑损伤的发病机制(JCB&M. 2017年)。我们
结论是,高血压大鼠中增强的WNK-Cab 39-NKCC 1信号传导与高血压大鼠中增加的
缺血性脑损伤的易感性,并作为抗高血压和抗缺血的新靶点
中风治疗我们开发了一种新的WNK-SPAK抑制剂ZT-1a,它显示出强大的神经保护活性
在缺血性中风的动物模型中(Nature Communications 2020)。从这项研究中获得的一项专利
申请(VA发明公开ID# 2018-313)“
ZT-1a及其衍生物在脑部的治疗应用
疾病”
已通过美国退伍军人事务部提交。将ZT-1a及其衍生物评估为新型药物
用于急性缺血性中风治疗的神经保护药物是创新的,将有益于退伍军人的健康。
在I 01 BX 004625资助的第二项研究中,我们将研究小胶质细胞-少突胶质细胞的作用。
在白色物质损伤和组织修复中的相互作用,并探索以胶质细胞为导向的治疗策略,
创伤性脑损伤小胶质细胞活化在白色物质损伤和组织修复中起作用。调节亲-
小胶质细胞/巨噬细胞的炎性和适应性表型对于少突胶质细胞分化是重要的,
髓鞘再生以及突触的重塑。我们最近发现Na/H交换异构体1蛋白
(NHE 1)介导的H+流出维持小胶质细胞内pH稳态以促进NADPH氧化酶
活化、自由基超氧化物产生和细胞因子分泌。我们报道了选择性删除
Cx 3cr 1-CreER;Nheflox/flox(Nhe 1 KO)小鼠中的小胶质细胞Nhe 1保留了少突胶质细胞,并改善了
在实验性局灶性缺血性中风模型中感觉运动功能恢复。Nhe 1 KO小鼠表现出
在对照皮质中APC+成熟少突胶质细胞计数增加,并保留白色物质完整性
撞击诱导TBI模型。特别是,TBI后给予NHE 1蛋白抑制剂HOE 642加速了
中风或TBI后小鼠的神经功能恢复。我们将进一步研究NHE 1蛋白在
调节TBI后髓鞘再生和组织修复中的小胶质细胞介导的炎症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dandan Sun其他文献
Dandan Sun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dandan Sun', 18)}}的其他基金
ShEEP Request for a High-Content Screening (HCS) Platform
ShEEP 请求建立高内涵筛选 (HCS) 平台
- 批准号:
10175276 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Long Non-Coding RNAs and Cerebral Angiogenesis in Ischemic Stroke
长非编码 RNA 与缺血性中风中的脑血管生成
- 批准号:
10605296 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Regulatory T cell as a restorative therapy for ischemic stroke
调节性 T 细胞作为缺血性中风的恢复疗法
- 批准号:
10261318 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Regulatory T cell as a restorative therapy for ischemic stroke
调节性 T 细胞作为缺血性中风的恢复疗法
- 批准号:
9619010 - 财政年份:2016
- 资助金额:
-- - 项目类别:
相似海外基金
Un/kindness, shame & resistance: the care of inpatients in NHS adult acute mental health units and how it might be improved
Un/善良,羞耻
- 批准号:
2885806 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Studentship
Post-Acute Care Transitions for Older Adult Medicare Beneficiaries with Serious Mental Illness
患有严重精神疾病的老年医疗保险受益人的急性后护理过渡
- 批准号:
10772386 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
474619 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Operating Grants
Investigating the impact acute inhalation of cannabis with a high content of delta-9-tetrahydrocannabinol has on myelination and microglia in adult and aged mice
研究急性吸入高含量 delta-9-四氢大麻酚的大麻对成年和老年小鼠髓鞘形成和小胶质细胞的影响
- 批准号:
485965 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship Programs
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
466358 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Operating Grants
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
预测顺铂介导的急性肾损伤的代谢组学:加拿大多中心成人和儿童研究
- 批准号:
402040 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
- 批准号:
18K16103 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Causal effect of time-varying driving pressures on mortality in mechanically ventilated, adult patients with acute respiratory distress syndrome
时变驱动压力对机械通气成年急性呼吸窘迫综合征患者死亡率的因果影响
- 批准号:
377313 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Studentship Programs
Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia
SETBP1 在成人 Ph 急性淋巴细胞白血病中的作用
- 批准号:
9315111 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Acute Inhibition of Adult-born Granule Cells and its Effect on Antidepressant Act
成体颗粒细胞的急性抑制及其抗抑郁作用
- 批准号:
8734273 - 财政年份:2013
- 资助金额:
-- - 项目类别: